Common Skin Rashes in Children
Primary Care of Patients With Cancer
Boards Qs
POEMs
AHA/ACC Hypertension Guidelines
100

A 6-year-old boy presents with a bright red, confluent erythema of both cheeks sparing the nasal bridge and perioral area ("slapped cheek") that appeared 2 days ago. He had a mild low-grade fever and coryza the week before. He is now afebrile and well-appearing. His mother asks if he can return to school.

Which diagnosis and return-to-school guidance is correct?

A. Scarlet fever - may return 24 hours after starting antibiotics
B. Erythema infectiosum (fifth disease) due to parvovirus B19 - once rash erupts, child is no longer contagious; may return to school
C. Hand-foot-and-mouth disease due to coxsackievirus - must stay home until all lesions crust over
D. Molluscum contagiosum - requires exclusion until lesions resolve
E. Measles - requires 4 days exclusion after rash onset

Correct Answer: B

Explanation:
Erythema infectiosum (fifth disease) is caused by human parvovirus B19, most common in ages 5-15 years. It has a 3-stage course: Stage 1 is the slapped cheek appearance sparing the nasal bridge/perioral region lasting 4-5 days. Stage 2 is pink macules on trunk/extremities/buttocks with central clearing creating a lacy/reticulated appearance, lasting up to 3 weeks. Stage 3 is recrudescence triggered by heat, sun, or stress for several weeks.

Key clinical pearl: Once the rash erupts, the child is no longer contagious - no exclusion required. In contrast, impetigo and scarlet fever require 24 hours after starting antibiotics, hand-foot-and-mouth disease requires being afebrile and able to participate (viral shedding continues for weeks), and molluscum, pityriasis rosea, and tinea require no exclusion (just cover lesions for tinea/impetigo).

Treatment is supportive. Complications to remember: transient aplastic crisis in chronic hemolytic disorders or immunocompromise, and arthralgias more common in adolescents/young adults.

100

A 62-year-old woman with stage II breast cancer on chemotherapy has well-controlled diabetes and hypertension. She asks what lifestyle measure is strongly recommended during cancer treatment to improve quality of life according to the AFP review.

A. Strict bed rest until chemotherapy completed
B. Consistent physical activity during cancer treatment
C. Complete avoidance of all physical activity due to fatigue
D. High-dose vitamin supplements instead of exercise
E. Fasting throughout treatment

Correct Answer: B. Consistent physical activity during cancer treatment

Explanation:

Consistent physical activity is recommended during cancer treatment to improve quality of life - Evidence rating A (meta-analysis of randomized controlled trials).

Strict rest and fasting are not recommended. Physical activity improves fatigue, depression, function, and quality of life during and after treatment.

100

A 68-year-old female presents with a history of episodic severe lower abdominal pain relieved by defecation. She has had a long history of constipation with normal to very firm stools. Her history and a physical examination are otherwise normal. A colonoscopy 3 years ago was normal. You diagnose constipation-predominant irritable bowel syndrome.

Which one of the following agents would be the most appropriate treatment for this patient?

What is the best initial management for this patient? 

A. Lactulose

B. Magnesium citrate

C. Milk of magnesia

D. Polyethylene glycol

E. Sodium phosphate

D. Polyethylene glycol

Hypertonic osmotic laxatives such as milk of magnesia, magnesium citrate, and sodium phosphate draw water into the bowel and should be used with caution in older adults and those with renal impairment because of the risk of electrolyte abnormalities and dehydration in patients with irritable bowel syndrome (IBS). Lactulose, also an osmotic laxative, should be avoided in patients with IBS because it is broken down by colonic flora and produces excessive gas. Polyethylene glycol, a long-chain polymer of ethylene oxide, is a large molecule that causes water to be retained in the colon, which softens the stool and increases the number of bowel movements. It is approved by the FDA for short-term treatment in adults and children with occasional constipation and is commonly prescribed for patients with IBS. It is considered safe and effective for moderate to severe constipation when used either daily or as needed.

100

A 28-year-old pregnant patient at 12 weeks gestation asks if taking acetaminophen (paracetamol) for fever will increase her child's risk of autism or ADHD. She has seen news reports linking the two.

Based on the 2026 systematic review and meta-analysis by D'Antonio et al., what is the best answer?

A. Prenatal acetaminophen exposure significantly increases the risk of autism spectrum disorder (ASD)
B. Prenatal acetaminophen exposure significantly increases the risk of ADHD and intellectual disability
C. Prenatal acetaminophen exposure during the first trimester, but not later, significantly increases the risk of neurodevelopmental disorders
D. No significant association was found between prenatal acetaminophen exposure and ASD, ADHD, or intellectual disability
E. Prenatal acetaminophen exposure decreases the risk of neurodevelopmental disorders

Correct Answer: D. No significant association was found

Explanation:

The meta-analysis of cohort studies failed to identify an association of prenatal acetaminophen exposure with autism spectrum disorders, ADHD, or intellectual disabilities in childhood. (Level of Evidence = 2a-)

Key Supporting Details:

  • Study Design: Systematic review and meta-analysis of cohort studies (various settings, self-funded/unfunded). Authors included 43 studies in the systematic review and 17 in the meta-analysis. They excluded studies that reported only unadjusted estimates and controlled for underlying maternal comorbidities and pharmacologic treatments before and during pregnancy.

  • Sibling-comparison subgroup analysis - the strongest data to control for familial confounding:

    • ASD: OR = 0.98 (95% CI, 0.93-1.03)
    • ADHD: OR = 0.95 (95% CI, 0.86-1.05)
    • Intellectual disability: OR = 0.93 (95% CI, 0.69-1.24)
  • All confidence intervals cross 1.0, indicating no statistically significant association.

  • Low risk of bias studies: 11 studies classified as low risk of bias showed the same lack of difference in outcomes.

  • Limitation: Authors were unable to perform subgroup analysis by trimester or frequency of intake because few studies reported those data, resulting in insufficient power for those estimates.

Clinical Application: For counseling, current best evidence from adjusted cohort studies does not support an increased risk of ASD, ADHD, or intellectual disability with prenatal acetaminophen use when confounding is controlled for. Acetaminophen remains the preferred antipyretic/analgesic in pregnancy when clinically indicated.

100

According to the 2025 AHA/ACC hypertension guideline, which statement about prevention and initial evaluation is correct?

A. Lifestyle interventions are only recommended after medication failure
B. A heart-healthy eating pattern such as the DASH diet is recommended for all adults to prevent and treat hypertension, with sodium limited to <2.3 g per day - goal <1.5 g per day
C. Initial evaluation of new hypertension should not include any laboratory testing
D. Exercise should be avoided in patients with hypertension
E. Dietary potassium and potassium salt substitutes should never be recommended

Correct Answer: B

Explanation:
Key Points from Guideline Summary:

  • Lifestyle interventions are recommended for ALL adults for hypertension prevention and treatment - not only after medication.
  • Dietary: DASH diet recommended for all patients. Other diets (Mediterranean, low-carbohydrate, vegetarian, low-fat) lower BP but less effectively. Sodium limited to <2.3 g/day, goal <1.5 g/day, with use of dietary potassium and potassium salt substitutes recommended (except in CKD or with drugs that reduce potassium excretion where monitoring required).
  • Weight loss: Loss of at least 5% of body weight recommended for overweight/obesity. BMI ≥27 kg/m² - incretin mimetics (GLP-1 receptor agonists) can be effective. BMI ≥35 kg/m² - bariatric surgery can improve BP.
  • Exercise: Structured programs with aerobic and resistance exercise recommended for all patients. Each 30 min weekly aerobic exercise reduces BP by ~2 mm Hg systolic / 1 mm Hg diastolic, up to 150 min/week. Transcendental meditation has best evidence for stress reduction.
  • Substance use: Limit alcohol to ≤1 drink/day women, ≤2 drinks/day men.
  • Initial evaluation: In addition to history and physical, ECG, CBC, basic metabolic panel, lipid profile, fasting glucose or A1C, TSH, urinalysis, urine albumin:creatinine ratio recommended, and laboratory testing repeated at least annually.

C, D, and E are opposite of guideline recommendations.

200

A 2-year-old child has a high fever but seems otherwise well. The rash from which one of the following conditions characteristically appears in young children after defervescence?  (check one)

 A. Measles.

 B. Rubella.

 C. Roseola infantum.

 D. Scarlet fever.

C. Roseola infantum. 

The classic roseola infantum rash is notable for its appearance after defervescence, which distinguishes it from measles and rubella. It presents in otherwise well-appearing children younger than 3 years with high fever for 3 to 5 days. The exanthem is characterized by erythematous, blanchable, morbilliform 2.5-mm macules and papules and typically begins on the trunk and spreads centrifugally, distinguishing it from measles and rubella, which tend to start on the face and spread to the trunk. Scarlet fever presents with fever, throat pain, headache, and rash. Clinical skin findings include diffuse fine erythematous macules and papules with sandpaper texture and flexural petechiae.

200

Your 75-year-old patient underwent radical prostatectomy for localized prostate cancer 6 months ago. He wants to know how much exercise is recommended to decrease his risk of recurrence. Which one of the following recommendations for moderate-intensity physical activity is most appropriate for this patient?  (check one)

 A. 15 minutes 5 days per week.

 B. 15 minutes daily.

 C. 30 minutes 3 days per week.

 D. 30 minutes 5 days per week.

 D. 30 minutes 5 days per week. 

Consistent physical activity is recommended for cancer survivors during treatment to improve quality of life. At least 30 minutes of moderate-intensity exercise is recommended at least 5 days per week. This is associated with lower risk of cancer recurrence and mortality, especially in survivors of colorectal, breast, and prostate cancers. 

200

A 34-year-old female presents with a 3-month history of a minimally productive cough. She has never smoked. She does not have any fever, weight loss, rhinorrhea, congestion, or heartburn. She does not have a known history of allergies or asthma and has tried over-the-counter cold remedies, cough syrups, and cough drops without significant relief. She is otherwise healthy and takes no medications. On examination her vital signs are normal. An ear, nose, and throat examination is remarkable for swollen nasal turbinates. A lung examination is normal. Given the duration of the cough, you order a chest radiograph, which is normal as well.

Which one of the following would be most appropriate at this point?  (check one)

 A. A trial of an intranasal corticosteroid

 B. A trial of an inhaled bronchodilator

 C. A trial of a proton pump inhibitor

 D. A sinus radiograph

 E. Referral for allergy testing

A. A trial of an intranasal corticosteroid 

According to the CDC, cough is the most common symptom resulting in primary care visits. Chronic cough in adults is defined as one that lasts 8 weeks or more. The workup should include a history focusing on potential triggers, as well as the identification of any red flags. If the physical examination is normal and the patient’s history does not indicate the cause of the cough, a chest radiograph is appropriate.

The most common cause of chronic cough in adults is upper airway cough syndrome. Patients might have nasal symptoms such as rhinorrhea or congestion. Physical findings can include swollen turbinates and posterior pharyngeal cobblestoning, or they can be unremarkable. Initial treatment may include the use of decongestants, oral or intranasal antihistamines, intranasal corticosteroids, or saline nasal rinses (SOR C). Symptoms should resolve within a few weeks, and referral for allergy testing can be considered if they are not resolved within 2 months. CT of the sinuses can be considered as well, but sinus radiographs are more specific.

Other common causes of chronic cough include asthma, nonasthmatic eosinophilic bronchitis, and GERD. If asthma is suspected, spirometry is indicated. If spirometry is positive for asthma, a trial of an inhaled bronchodilator is indicated. If there are other indications of GERD such as heartburn, globus sensation, or hoarseness, an antacid or a trial of a proton pump inhibitor is indicated.

200

A 66-year-old man with paroxysmal atrial fibrillation and hypertension (CHA2DS2-VASc score 2) underwent successful catheter ablation 18 months ago. Success was confirmed by Holter monitoring, including a 48-hour monitor within the last 2 months, with no recurrent atrial fibrillation. He currently takes rivaroxaban 15 mg daily and asks if he can stop anticoagulation.

Based on the OCEAN trial, which statement best describes the risks and benefits of continuing rivaroxaban versus switching to low-dose aspirin in this population?

A. Rivaroxaban significantly reduces the composite of stroke, systemic embolism, and covert stroke compared with aspirin
B. Aspirin significantly increases major bleeding compared with rivaroxaban
C. There is no significant difference in stroke/systemic embolism/covert stroke, with a numerically higher rate of major bleeding with rivaroxaban, and the trial was stopped early for futility
D. Rivaroxaban reduces cardiovascular mortality but has no effect on stroke
E. Aspirin is contraindicated after catheter ablation due to high thromboembolic risk

Correct Answer: C

Explanation:

Clinical Question: In patients with successful catheter ablation for atrial fibrillation at least 1 year earlier and a CHA2DS2-VASc score ≥1 (men) or ≥2 (women), is there a net benefit to continued anticoagulation with rivaroxaban versus low-dose aspirin?

Study Design: Randomized controlled trial (single-blinded, concealed allocation, intention-to-treat). Patients with mean age 66 years, ~75% with single ablation only, and ~66% with paroxysmal atrial fibrillation were randomized to rivaroxaban 15 mg daily or low-dose aspirin and followed for a median of 3 years. MRI was performed at baseline and end of follow-up to detect covert embolic strokes.

Key Results:

  • Primary outcome (stroke, systemic embolism, or covert stroke): rivaroxaban 5 patients (0.8%) vs aspirin 9 patients (1.4%); absolute risk difference 0.6% (95% CI, -1.8 to 0.5) - no significant difference.
  • Major bleeding occurred numerically more often with rivaroxaban (1.6% vs 0.6%; HR 2.5; 95% CI, 0.8-8.0).
  • The trial was stopped early for futility.
  • Overall stroke rate was low and similar to that in people without a history of atrial fibrillation.

Bottom Line: In patients who had a successful catheter ablation for atrial fibrillation at least 1 year earlier with Holter-confirmed success, stopping the anticoagulant and switching to aspirin is safe. There is no net benefit of continued rivaroxaban for preventing stroke and embolism, and it may increase bleeding risk. (Level of Evidence = 1b)

Teaching Point: For patients with successful AF ablation >1 year ago and no recurrence on monitoring, the OCEAN trial supports de-escalation from rivaroxaban to aspirin in appropriately selected patients with continued low thromboembolic risk.

200

A 52-year-old man has an average blood pressure of 146/92 mm Hg on two office visits using a validated oscillometric device with correct technique. He has no history of cardiovascular disease, diabetes, or chronic kidney disease. According to the 2025 AHA/ACC guideline, how should his hypertension be classified and what is the recommended initial management?

A. Normal blood pressure - no further action
B. Elevated blood pressure - reassurance only
C. Stage 2 hypertension - start lifestyle interventions for all adults plus a single-pill combination of 2 drugs (ACE inhibitor or ARB plus thiazide-type diuretic or long-acting dihydropyridine calcium channel blocker), with target systolic <130 mm Hg and encouragement to reach <120/<80 mm Hg if tolerated
D. Stage 1 hypertension - start lifestyle only and recheck in 1 year
E. Hypertensive emergency - admit to intensive care

Correct Answer: C

Explanation:

Categories per guideline:

  • Normal: <120 and <80 mm Hg
  • Elevated: 120-129 systolic and <80 diastolic
  • Stage 1 hypertension: 130-139 or 80-89 mm Hg
  • Stage 2 hypertension: ≥140 systolic or ≥90 diastolic

This patient at 146/92 mm Hg has stage 2 hypertension.

Key Management Points:

  1. Lifestyle interventions recommended for all adults for prevention and treatment - DASH diet, sodium <2.3 g/day - goal <1.5 g/day, potassium and salt substitutes, weight loss ≥5% if overweight/obesity, aerobic + resistance exercise, limit alcohol ≤1 drink/day women, ≤2 drinks/day men.

  2. Treatment thresholds: Medical treatment recommended at average ≥140/90 mm Hg for all patients, and at ≥130 systolic for patients with cardiovascular disease, chronic kidney disease, diabetes, or 10-year cardiovascular risk ≥7.5% using PREVENT calculator.

  3. Drug choice: Patients with stage 1 can start a single agent with titration. For systolic ≥140 or diastolic ≥90, guideline recommends single-pill combination of two medications: ACE inhibitor or ARB + thiazide-type diuretic or long-acting dihydropyridine CCB as first-line. Include ACE inhibitor or ARB if chronic kidney disease.

  4. BP Target: <130 mm Hg systolic for all patients, with encouragement to reach <120 mm Hg systolic and <80 mm Hg diastolic if tolerated.

  5. Follow-up: Check basic metabolic panel (potassium, sodium, creatinine) 2-4 weeks after initiation or dose adjustment of ACE inhibitor, ARB, diuretic, or mineralocorticoid receptor antagonist.

  6. Correct office measurement: Avoid caffeine, exercise, smoking ≥30 min before, empty bladder, sitting feet on floor legs uncrossed back supported >5 min, correct cuff at heart level on supported bare arm, no talking or cell phone during rest/measurement, ≥2 readings ≥1 min apart. Home and ambulatory monitoring are more predictive than office and useful to exclude white coat hypertension and detect masked hypertension.

300

A 10-year-old boy had a low-grade fever, coryza, sore throat, malaise, myalgia, nausea, and headache for several days that have resolved. He now has a rash on his chest and arms, and his mother is worried it might be measles. On questioning, the child says he has developed aches in both wrists. He is current on vaccinations. Which one of the following is the most likely diagnosis? 

 A. Molluscum contagiosum.

 B. Erythema infectiosum.

 C. Pityriasis rosea.

 D. Papular acrodermatitis of childhood.

B. Erythema infectiosum. 

In erythema infectiosum, a prodrome like the one this patient experienced precedes the rash. The rash initially has a slapped cheek appearance and then spreads to the trunk, extremities, and buttocks, with greater prominence on extensor surfaces. Adolescents and young adults are more likely than younger children to experience arthralgia. Molluscum contagiosum causes multiple clustered small, firm, dome-shaped papules that are pearly white or the same color as surrounding skin and is most common in children ages 1 to 4 years. Pityriasis rosea begins as a herald patch on the trunk and spreads several weeks later to the back in a Christmas tree pattern. Papular acrodermatitis of childhood is characterized by acute-onset pink to red-brown papules and papulovesicles symmetrically involving the cheeks, extensor extremities, and sometimes buttocks, with sparing of the trunk. 

300

A 45-year-old woman who is undergoing treatment for stage I breast cancer presents for routine follow-up. She currently uses tobacco. She recently underwent lumpectomy and is scheduled to receive radiotherapy. Her body mass index (BMI) is 24 kg/m2, and her diet includes red meat four nights per week. Which one of the following is recommended for this patient?  (check one)

 A. Baseline transthoracic echocardiography prior to radiotherapy because of potential toxicity.

 B. Smoking cessation to reduce the risk of all-cause mortality.

 C. Increase red meat consumption to most days of the week to improve iron stores during radiotherapy.

 D. Encourage the patient to gain weight to a BMI of 27 kg/m2 to help better tolerate radiotherapy.

 B. Smoking cessation to reduce the risk of all-cause mortality. 

Smoking cessation is recommended for all patients with cancer and is associated with reduced risk of cardiovascular disease and all-cause mortality. Baseline transthoracic echocardiography is recommended for patients receiving cardiotoxic therapies, such as doxorubicin, but is not routinely indicated for patients undergoing radiotherapy alone. Eating a predominantly plant-based diet and maintaining a body mass index less than 25 kg/m2 are associated with lower risk of cancer recurrence and mortality, especially in survivors of colorectal, breast, and prostate cancers.

300

A 48-year-old male presents with pain in the right antecubital fossa after lifting a trailer in his garage. On examination you note ecchymosis and tenderness in the antecubital fossa. You suspect a possible distal biceps tendon rupture.

Which one of the following would be most appropriate at this point?

A. A Speed’s test

B. Plain radiographs of the elbow

C. MRI of the elbow

D. A local corticosteroid injection

E. Referral for physical therapy

C. MRI of the elbow

Distal biceps tendon ruptures are relatively uncommon, accounting for about 3% of tendon ruptures. In a patient with a suspected distal biceps tendon rupture, clinical signs can be unreliable and MRI imaging is the test of choice. Bony abnormalities do not contribute to the evaluation of this tendon. A Speed’s test is used to evaluate pain related to the long head of the biceps tendon. Surgical repair is the treatment of choice when the tendon is ruptured. Physical therapy and local corticosteroid injections are not beneficial.

300

A 54-year-old man has severe hypertriglyceridemia with fasting triglycerides 820 mg/dL despite diet and fibrate therapy. He had one prior episode of acute pancreatitis. His BMI is 31, A1c 6.2%, and he has no history of cardiovascular disease. He asks about olezarsen (Tryngolza), a new subcutaneous injection.

Question:
Based on the combined CORE-TIMI 72a and 72b trials, which statement best describes the efficacy and safety of olezarsen in patients with fasting triglycerides ≥500 mg/dL (5.65 mmol/L)?

A. Olezarsen 50 mg and 80 mg every 4 weeks reduced triglycerides by <20% compared with placebo and did not reduce acute pancreatitis
B. Olezarsen reduced triglycerides by 63% (50 mg) and 70% (80 mg) vs 0% with placebo and significantly reduced acute pancreatitis events (1.0 vs 6.2 events per 100 person-years; IRR 0.15; 95% CI 0.05-0.40; NNT 20 over 1 year)
C. Olezarsen significantly increased cardiovascular events and significantly increased hepatic steatosis compared with placebo
D. Olezarsen is an oral PCSK9 inhibitor that lowers LDL-C by 50% and is inexpensive for severe hypertriglyceridemia
E. The benefit of olezarsen was limited to patients with familial chylomicronemia syndrome; patients with triglycerides 500-1000 mg/dL without genetic syndrome had no benefit

Correct Answer: B

Explanation:

Clinical Question: Does olezarsen reduce the risk of acute pancreatitis in people with severe hypertriglyceridemia (≥500 mg/dL)?

Study Design: Combined report of two identical randomized controlled trials (double-blinded, modified intention-to-treat). Patients with fasting triglycerides ≥500 mg/dL randomized to olezarsen 80 mg, olezarsen 50 mg, or placebo as subcutaneous injection every 4 weeks for 48 weeks, followed for 12 months. Mean age 54 years, median triglyceride 793 mg/dL, ~14-25% had prior acute pancreatitis. ~10% in each group dropped out.

Key Results Supporting B:

  • Highly effective triglyceride lowering: -63% with 50 mg and -70% with 80 mg vs 0% with placebo.
  • Patient-oriented outcome - acute pancreatitis: Significantly less likely with pooled olezarsen vs placebo: 1.0 vs 6.2 events per 100 person-years; incidence rate ratio 0.15 (95% CI 0.05-0.40). This corresponds to NNT = 20 over 1 year to prevent one pancreatitis event.
  • Safety: Adverse events leading to discontinuation were similar: 2.0% placebo, 3.4% with 50 mg, 4.3% with 80 mg. No difference in cardiovascular events. Hepatic steatosis was nonsignificantly more common: 2.4% vs 1.1% (p=0.17).
  • Mechanism / Cost: Olezarsen targets mRNA to decrease production of apolipoprotein C-III. Originally approved as orphan drug for familial chylomicronemia syndrome, now studied to expand indication. Expensive - approximately $600,000 per year for patients with familial chylomicronemia syndrome.

Why Other Options Are Wrong:

  • A - Opposite of results: Triglyceride reduction was 63-70%, not <20%, and pancreatitis was significantly reduced.
  • C - Misstates safety: No difference in cardiovascular events. Hepatic steatosis was not significantly increased.
  • D - Wrong mechanism and cost: Olezarsen is not an oral PCSK9 inhibitor or LDL-C drug; it is a subcutaneous anti-apoC-III mRNA-targeted therapy given every 4 weeks, and is very expensive.
  • E - Wrong population: Trials enrolled all patients with fasting triglycerides ≥500 mg/dL (mean 793 mg/dL), not only familial chylomicronemia syndrome; benefit was shown in this broader severe hypertriglyceridemia population.

Bottom Line: Olezarsen significantly lowers triglycerides and reduces episodes of acute pancreatitis (NNT=20 over 1 year) in severe hypertriglyceridemia, with similar discontinuation rates to placebo, but cost is very high. (Level of Evidence = 1b)

300

A 58-year-old man with no history of cardiovascular disease, diabetes, or chronic kidney disease has an average office BP of 136/84 mm Hg on 2 separate visits, confirmed with validated oscillometric device using correct protocol (feet on floor, back supported >5 min, correct cuff at heart level on bare arm, no talking, 2+ readings ≥1 min apart). Home BP averages 134/82 mm Hg. His PREVENT 10-year cardiovascular risk is 8.5%. He has been counseled on DASH diet, sodium reduction and exercise for 4 months without BP improvement.

Per the 2025 AHA/ACC guideline, what is the recommended next step?

A. Continue lifestyle only, do not start medication because systolic BP <140 mm Hg
B. Start medical treatment, because threshold is ≥130 mm Hg systolic in patients with 10-year CVD risk ≥7.5% using PREVENT calculator, with target systolic BP <130 mm Hg and encouragement to reach <120/<80 mm Hg if tolerated
C. Start medication only if BP reaches ≥150/95 mm Hg
D. Target systolic BP <140 mm Hg only
E. Repeat labs weekly and defer medication regardless of risk

Correct Answer: B

Explanation:
AHA/ACC Categories and Treatment Thresholds:

  • Normal: <120/<80 mm Hg
  • Elevated: 120-129/<80 mm Hg
  • Stage 1 hypertension: 130-139 or 80-89 mm Hg
  • Stage 2 hypertension: ≥140 or ≥90 mm Hg

Treatment Thresholds:

  • Medical treatment recommended for all patients at average systolic BP ≥140 or diastolic ≥90 mm Hg to reduce cardiovascular events and mortality.
  • Treatment at systolic ≥130 mm Hg recommended for patients with cardiovascular disease, chronic kidney disease, diabetes, or 10-year cardiovascular risk ≥7.5% using PREVENT calculator.
  • For low-risk patients (10-year risk <7.5%), initiate treatment after 3-6 months of lifestyle modifications if BP not at goal (systolic <130). This last recommendation is the most controversial, based on a single Brazilian study of 730 prehypertensive patients, and differs from Hypertension Canada which does not recommend it.

This patient: Stage 1 hypertension (136/84) + PREVENT risk 8.5% (≥7.5%) = qualifies for medication now after lifestyle trial. BP is confirmed with both office (with correct protocol) and home monitoring - useful to confirm hypertension and exclude white coat hypertension. Home monitoring typically aligns with office up to 130/80, above that home readings typically lower than office, but both predict outcomes better than office alone.

BP Target: Systolic <130 mm Hg for all patients, with encouragement to reach <120 mm Hg and diastolic <80 mm Hg if tolerated.

Medication choice for stage 1: Can begin single antihypertensive, with dose titration. For stage 2 (≥140/90), single-pill combination of 2 drugs recommended: ACE inhibitor or ARB + thiazide-type diuretic or long-acting dihydropyridine CCB as first-line. For CKD include ACEi/ARB; for history of ischemic stroke/TIA/intracerebral hemorrhage consider ACEi/ARB/thiazide.

The patient already completed 3-6 month lifestyle intervention without control, so medication is now indicated.

400

A 4-year-old girl presents with multiple superficial erosions with honey-colored crusting around the mouth and on the arms for 3 days. She has 3 small lesions, covering <1% body surface area, no fever, and no bullae. A 7-year-old brother has similar lesions. Which statement best describes diagnosis and evidence-based management?

A. Nonbullous impetigo caused by Staphylococcus aureus or Streptococcus pyogenes; localized disease <2% body surface area can be treated with topical mupirocin; exclusion until 24 hours after starting antibiotics or lesions crusted/healed
B. Bullous impetigo caused only by Streptococcus pyogenes; requires oral penicillin for all cases
C. Molluscum contagiosum - characterized by dome-shaped umbilicated papules; treat with oral cephalosporin to prevent rheumatic fever
D. Atopic dermatitis - intensely pruritic papules/vesicles in flexural areas; treat with systemic antifungals
E. Scarlet fever - sandpaper-like rash with Pastia lines; treat with supportive care only

Correct Answer: A

Explanation:
Nonbullous impetigo begins as maculopapular lesions evolving into vesicles that rupture forming superficial erosions with brownish-gold honey-colored crusting, typically periorally and on extremities. Caused by S. aureus or S. pyogenes. Most common in ages 2-5 years. Highly contagious via direct/indirect skin contact.

Bullous impetigo is caused only by S. aureus, with large flaccid bullae that rupture leaving erosions with collarette of brown/golden scale, found on trunk, extremities, intertriginous areas, most common <2 years.

Management (SORT ratings):

  • Up to 50% resolve spontaneously in 7-10 days, but antibiotics speed resolution and reduce spread.
  • Topical antibiotics (e.g., mupirocin) effective for limited, uncomplicated nonbullous impetigo <2% body surface area (SORT A) - this patient qualifies.
  • Oral antibiotics indicated for >2% BSA, complications (abscess, deeper infection), poor response to topical, recurrence, or infants/neonates (SORT C): preferably cephalosporins or amoxicillin/clavulanate; if culture confirms only streptococci - oral penicillin preferred; if high MRSA prevalence or MRSA positive - clindamycin or doxycycline.

Return to school/childcare: 24 hours after starting antibiotics or when lesions are crusted/healed, with other lesions covered.

Distractors: Molluscum is umbilicated dome papules sparing palms/soles, self-limited months to years, observation sufficient. Atopic dermatitis is flexural pruritic disease treated with emollients/topical steroids, not antifungals. Scarlet fever requires antibiotics within 9 days to prevent acute rheumatic fever.

400

A 58-year-old man with prostate cancer on androgen deprivation therapy (ADT) and type 2 diabetes presents for primary care follow-up. He has hypertension and hyperlipidemia. According to the review, which statement best reflects correct primary care management for patients with cancer and comorbid conditions?

A. Blood glucose control does not affect oncologic surgery or wound healing, so de-intensification is always preferred
B. Cardiovascular disease screening and risk assessment should be performed for patients with cancer who have cardiac risk factors or exposures known to cause cardiac complications
C. Cardiovascular risk is lower in cancer survivors than in the general population and no additional screening is needed
D. Adults with cancer should not receive GLP-1 receptor agonists or SGLT2 inhibitors due to cancer progression risk
E. Plant-based diet and exercise have no effect on cancer recurrence

Correct Answer: B

Explanation:
SORT Recommendations:

  • Control of blood glucose should be optimized in patients with cancer and diabetes to prevent delays in oncologic surgeries, improve wound healing, and decrease difficulty managing chemotherapy - Evidence rating C (clinical review). ~50% of patients with cancer have diabetes or prediabetes; cancer patients are 1.4x more likely to have diabetes. Poor control delays surgery and impairs healing. Management should favor agents with decreased morbidity/mortality - e.g., SGLT2 inhibitors like empagliflozin for heart failure history and GLP-1 agonists like semaglutide or tirzepatide if indicated (diabetes/obesity) - they reduce cardiovascular morbidity/mortality. They are not contraindicated solely due to cancer except specific contraindications like history of medullary thyroid cancer/MEN2 for GLP-1.

  • Given increased risk for CVD and heart failure among adult cancer survivors, screening for CVD and cardiovascular risk assessment should be performed for patients with cancer and cardiac risk factors or oncologic treatment exposures known to cause cardiac complications - Evidence rating B (large epidemiologic studies, expert opinion). Adult survivors have ~37% increased risk of any CVD and 52% increased risk of heart failure vs no cancer history, independent of traditional risk factors. Risk varies by cancer type: significant for breast, lung, colorectal, hematologic/lymphatic malignancies; no significant CVD risk associated with prostate cancer itself, but ADT increases hypertension, hyperlipidemia, diabetes and CVD is leading cause of death in prostate cancer patients.

  • Healthy lifestyle: plant-based or Mediterranean diet, regular exercise, smoking cessation, limited alcohol, weight management do influence long-term cardiovascular outcomes and are associated with lower recurrence/mortality.

Why the other answers are wrong:
A - opposite; optimization prevents delays/impaired healing
C - opposite; risk substantially increased
D - incorrect; GLP-1 and SGLT2 inhibitors should be considered when indicated
E - incorrect; associated with lower recurrence/mortality

400

A 72-year-old male with type 2 diabetes mellitus sees you for routine follow-up. He takes metformin (Glucophage), 1000 mg twice daily. He is sedentary and does not adhere to his diet. His BMI is 32 kg/m2. The examination is otherwise within normal limits. His hemoglobin A1c is 9.5%.

Which one of the following is recommended by the American Diabetes Association to better control his blood glucose? 

A. Start an intensive diet and exercise program for weight loss

B. Start home monitoring of blood glucose with close follow-up

C. Start basal insulin at 10 units/day

D. Stop metformin and start a sulfonylurea

E. Stop metformin and start a basal and bolus insulin regimen

C. Start basal insulin at 10 units/day

According to the American Diabetes Association’s 2018 guidelines for the management of diabetes, a healthy person with a reasonable life expectancy should have a hemoglobin A1c goal of <7%. Metformin is recommended as first-line therapy as long as there are no contraindications. If the hemoglobin A1c is not at the goal or is ≥9%, then adding another agent to metformin is recommended. Basal insulin at 10 units/day is an acceptable choice for additional therapy to improve blood glucose control. Diet, exercise, and home monitoring of blood glucose are recommended in addition to starting another agent for blood glucose control.

400

A 31-year-old mother at 6 weeks postpartum screens positive for postnatal depression with an Edinburgh Postnatal Depression Scale (EPDS) score of 14. She is hesitant to start medication and asks about non-pharmacologic community options. You recall the SHAPER-PND trial of mother-baby singing groups.

Question:
Based on the SHAPER-PND trial, which statement best describes the intervention and its effect on postnatal depression symptoms?

A. Weekly mother-baby singing groups (8-12 dyads, circle format with songs and simple instruments - Melodies for Mums) significantly reduced EPDS scores compared with existing community mother-baby activities at 10 weeks (10.7 vs 12.2, p=0.023) and 36 weeks (9.85 vs 11.4, p=0.026)
B. Singing groups were no different from control activities, with no clinically significant improvement in either group
C. The trial enrolled only mothers with severe major depression requiring hospitalization and showed singing worsened depressive symptoms
D. The singing intervention consisted of individual online music therapy sessions without infant involvement and was superior to antidepressants
E. Benefits were seen only at 10 weeks and disappeared by 36 weeks, with no sustained difference

Correct Answer: A

Explanation:

Clinical Question: What is the effect of participation in a weekly singing group on symptoms of postpartum (postnatal) depression?

Study Design: Randomized controlled trial (nonblinded, concealed allocation, intention-to-treat), outpatient setting, government and foundation funding. Level of Evidence = 1b-.

Key Details Supporting A:

  • Population: 199 mothers recruited via social media and primary care with postnatal depression defined as EPDS score ≥10; >80% had score >13, which qualifies for treatment. This is a mild-to-moderate community population, not hospitalized severe depression.
  • Intervention: Weekly singing group of 8-12 mother-baby pairs sitting in a circle, taught range of songs and used simple musical instruments (Melodies for Mums) vs existing community mother-baby activities control.
  • Results: Scores decreased by clinically significant amount in both groups, but singing group had significantly lower average scores:
    • Week 10: 10.7 vs 12.2 (p=0.023)
    • Week 36: 9.85 vs 11.4 (p=0.026)
      This demonstrates both short-term and sustained benefit to 36 weeks.

Why Other Options Are Wrong:

  • B - Opposite of results: Both groups improved clinically significantly, but singing group was statistically superior at both time points.
  • C - Wrong population and direction: Trial enrolled community mothers with EPDS ≥10 via primary care/social media, not hospitalized severe depression, and singing reduced - not worsened - symptoms.
  • D - Wrong intervention description: Intervention was in-person group circles with baby present using songs/instruments, not individual online therapy without infant, and comparator was community mother-baby activities, not antidepressants.
  • E - Wrong timeline: Difference was maintained at both 10 weeks and 36 weeks, indicating sustained benefit beyond the intervention period.

Bottom Line: For mothers with postnatal depression, involvement in a weekly community singing group with other mothers and their babies reduced symptoms more than participating in other mother-baby activities. This approach might be useful and inexpensive for practices or communities in which postnatal depression is common.

400

A 64-year-old woman has repeat standardized blood pressure measurements that average 137/91 mm Hg despite treatment with maximum doses of lisinopril, hydrochlorothiazide, and amlodipine. Despite an extensive review of symptoms, she reports no other concerns. According to the American Heart Association/American College of Cardiology (AHA/ACC) guidelines, which one of the following next steps is most appropriate?  (check one)

 A. Order computed tomography angiography of the renal arteries.

 B. Evaluate for kidney denervation.

 C. Obtain renin activity and plasma aldosterone levels.

 D. Order a sleep study independent of symptoms or clinical risk.

 C. Obtain renin activity and plasma aldosterone levels. 

Screening for primary aldosteronism is recommended because this patient has resistant hypertension. This condition affects up to 22% of patients with stage 2 hypertension. Screening involves measurement of plasma aldosterone and renin activity. Although renal artery stenosis can occur with atherosclerosis and be diagnosed with computed tomography angiography, stenting interventions do not improve outcomes. Kidney denervation has uncertain effectiveness and should be considered only after pharmacotherapy is optimized. Sleep study testing should be reserved for patients with symptoms or clinical risk of sleep apnea; the blood pressure benefit of combined continuous positive airway pressure and weight loss is seen only in patients with moderate to severe disease.

500

A 9-year-old boy presents with a 3-week history of a scaly, circular, pruritic patch on the scalp with broken hairs at the surface ("black-dot" appearance) and tender posterior cervical lymphadenopathy. A second patient, his 11-year-old sister, has a single 4-cm oval pink plaque with trailing scale on her trunk followed 10 days later by numerous smaller oval lesions aligned along Langer lines in a Christmas tree pattern on her back, with moderate pruritus.

What is the correct diagnosis and treatment for each?

A. Both have tinea corporis - treat both with topical terbinafine twice daily for 2-6 weeks + 2cm margin and 1 week beyond resolution
B. Boy: tinea capitis - requires oral systemic antifungal (griseofulvin 20 mg/kg/day for 6-8 weeks or weight-based terbinafine 62.5 mg <20kg, 125 mg 20-40kg, 250 mg >40kg daily for 4-6 weeks; obtain fungal culture at diagnosis; lab monitoring not needed in healthy children); no school exclusion but cover lesions; Girl: pityriasis rosea - self-limited 2-8 weeks, treat pruritus with oral antihistamines ± topical/oral steroids, no exclusion
C. Boy: atopic dermatitis - treat with topical steroids and emollients; Girl: scarlet fever - treat with 10-day penicillin/amoxicillin to prevent rheumatic fever
D. Boy: pityriasis alba - treat with topical calcineurin inhibitors; Girl: erythema infectiosum - supportive care, no longer contagious after rash
E. Boy: molluscum contagiosum - observation for months-years; Girl: hand-foot-and-mouth disease - supportive care, avoid topical lidocaine in mouth

Correct Answer: B

Explanation:
Tinea capitis vs. tinea corporis is a critical treatment distinction:

Tinea capitis: Circular, scaly pruritic scalp patches with broken hair shafts (black-dot tinea capitis) ± boggy abscess with scarring alopecia (kerion) + posterior cervical lymphadenopathy. Requires systemic oral antifungals - topical agents do not penetrate hair follicles.

  • First-line: Oral micronized griseofulvin 20 mg/kg/day for 6-8 weeks OR weight-based oral terbinafine daily for 4-6 weeks: 62.5 mg/day if <20 kg, 125 mg/day if 20-40 kg, 250 mg/day if >40 kg. For most cases terbinafine 4-6 weeks is as effective as griseofulvin 6-8 weeks.
  • Exception: Terbinafine less effective for Microsporum canis - griseofulvin preferred.
  • Best practice: Obtain fungal culture at diagnosis to guide therapy due to variable sensitivities and long course.
  • Monitoring: Lab monitoring not indicated in healthy children on standard duration.
  • Adjunct: Topical antifungal shampoos decrease spore shedding/transmission but do not treat infection.
  • Return to school: No exclusion required; cover lesions if possible. Avoid combination steroid/antifungal preparations (steroid worsens fungal infection → tinea incognito) and avoid nystatin (ineffective for dermatophytes).

Tinea corporis/cruris/pedis: Annular pink pruritic plaques with scaly raised borders and central clearing. Usually treatable with topical antifungals twice daily for 2-6 weeks, including 2 cm of normal surrounding skin and continuing 1 week after apparent resolution; allylamines (terbinafine, butenafine) more effective than azoles.

Pityriasis rosea: Self-limited condition linked to HHV-6/7 reactivation, most common ages 10-35 years. Begins in 50-90% with herald patch: single large 2-5 cm oval pink patch with peripheral collarette scale and subtle central clearing on trunk, followed days to weeks later by numerous smaller similar lesions aligned longitudinally along Langer lines creating Christmas tree pattern on back, extending to proximal extremities/neck. Duration typically 2-8 weeks but can last months. Pruritus in ~50%, moderate-severe in some. No school exclusion - not contagious. Treatment of pruritus: oral antihistamines + mild-to-moderate potency topical or oral steroids reduce pruritus (SORT B). Evidence for acyclovir mixed → reserve for severe cases. Do not use erythromycin routinely.

500

You review oncologic emergencies and treatment adverse effects for a teaching session. Which pairing of condition / associated cancer-treatment and initial management is most accurate per the review and Table 4?

A. Tumor lysis syndrome - most associated with small cell lung cancer - treat with fluid restriction and hypertonic saline
B. Hypercalcemia of malignancy - seen with multiple myeloma, breast, squamous head/neck, lung, kidney cancers - presents with confusion, polyuria, constipation, nausea - initial management aggressive IV hydration to euvolemia plus calcitonin/IV bisphosphonates
C. Febrile neutropenia - defined as single temperature ≥100.0°F and ANC <1000/µL - observe without antibiotics if clinically stable
D. Tamoxifen - used only post-menopausally, increases osteoporosis risk and has no thrombotic risk; aromatase inhibitors increase clot and uterine cancer risk
E. Chemotherapy-related peripheral neuropathy from platinum agents - best prevention is routine gabapentin, calcium/magnesium, and vitamins B/E

Correct Answer: B

Explanation:

  • Tumor lysis syndrome: Associated with hematologic malignancies (particularly acute leukemia) and high-grade lymphomas, solid tumors - NOT small cell lung cancer (SIADH is associated with small cell). Presents with azotemia, hyperphosphatemia, hyperkalemia, hyperuricemia, acute kidney failure, hypocalcemia. Management: aggressive IV hydration, uric acid-lowering agents (allopurinol, rasburicase), correction electrolytes. Fluid restriction + hypertonic saline is for SIADH.

  • Hypercalcemia of malignancy - Correct in B: Multiple myeloma, breast, squamous cell head/neck, lung, kidney, cervix cancers. Symptoms: confusion, weakness, anorexia, thirst, constipation, nausea/vomiting, decreased urine output, possible coma. Workup: calcium, PTH, electrolytes. Management: aggressive IV hydration to euvolemia, calcitonin, IV bisphosphonates.

  • SIADH: Small cell lung cancer, presents with hyponatremia, nausea, vomiting, muscle weakness - managed with fluid restriction, slow correction with hypertonic saline, tolvaptan - distractor in A.

  • Febrile neutropenia - Definition strict: Single axillary/oral temperature ≥101.3°F (38.5°C) OR sustained ≥100.4°F (38°C) for 1 hour AND ANC <500/µL (0.5 x 10⁹/L). Occurs with current chemotherapy. Management: CBC, blood/urine cultures, consider respiratory viral panel, empiric antibiotics immediately - never observe. C is wrong on both definition and management.

  • Venous thromboembolism: Advanced-stage cancers, chemotherapy, tamoxifen - presents with dyspnea, chest pain, tachycardia, unilateral leg swelling/pain - requires imaging (CT pulmonary angiography, duplex) and anticoagulation.

Hormone therapy nuances (distractor D reversed):

  • Tamoxifen: can be used pre- and post-menopausal, associated with increased blood clots, uterine cancer, stroke, but protective against bone demineralization
  • Aromatase inhibitors (letrozole): only postmenopausal (including ovarian suppression), do NOT have clot/uterine cancer/stroke risk, but do increase hyperlipidemia, joint pain, fatigue, osteoporosis

Neuropathy prevention (distractor E):

  • Peripheral neuropathy risks: vinca alkaloids, taxanes, platinum agents, bortezomib, preexisting neuropathy/diabetes
  • Prevention: no evidence-based pharmacologic prevention; NOT recommended: amitriptyline, calcium/magnesium, cannabinoids, carbamazepine, gabapentin, pregabalin, glutamate, metformin, acetylcysteine, omega-3, venlafaxine, vitamins B/E. May consider cryotherapy/compression/exercise. Treatment: duloxetine (preferred), exercise, acupuncture, scrambler therapy.

Additional pearl: Bupropion decreases tamoxifen effectiveness via CYP2D6 - avoid; consider alternative antidepressant.

500

A 47-year-old male presents with bilateral lower extremity edema of undetermined etiology extending to the proximal lower extremities, associated with fatigue. His lipid levels were also very high on recent testing. He does not take any daily medications and his thyroid function is normal. The only significant findings on examination are lower extremity edema and some periorbital edema.

Which one of the following urine tests could help confirm the most likely diagnosis?  

A. Crystals

B. Ketones

C. pH

D. Protein

E. Specific gravity

D. Protein

Nephrotic syndrome includes peripheral edema, heavy proteinuria, and hypoalbuminemia. Hyperlipidemia also occurs frequently and can be significant. Nephrotic-range proteinuria is a spot urine showing a protein/creatinine ratio >3.0–3.5 mg protein/mg creatinine or a 24-hour urine collection showing >3.0–3.5 g of protein. Testing urine for ketones, pH, specific gravity, or crystals does not help to diagnose nephrotic syndrome.

500

A 67-year-old man with paroxysmal atrial fibrillation, hypertension, and heart failure (CHA2DS2-VASc = 3) underwent successful catheter ablation 16 months ago. He had a single ablation procedure. A 48-hour Holter monitor 6 weeks ago showed no atrial fibrillation recurrence. He is currently taking rivaroxaban and has no bleeding history. He asks about long-term stroke prevention.

You counsel him based on the OCEAN trial.

Question:
Which statement most accurately reflects the design and results of the OCEAN trial in this population?

A. Patients with CHA2DS2-VASc ≥2 (men) or ≥3 (women) and successful ablation within 6 months were randomized to rivaroxaban 20 mg daily vs aspirin 81 mg daily, with a primary endpoint of clinical stroke alone
B. Rivaroxaban 15 mg significantly reduced the primary composite of stroke, systemic embolism, and covert embolic stroke compared with aspirin (0.8% vs 1.4%, p < 0.05 for superiority)
C. In patients with successful ablation ≥1 year ago, CHA2DS2-VASc ≥1 (men) or ≥2 (women), and Holter-confirmed success including 48-hour monitoring within 2 months of enrollment, the primary composite occurred in 0.8% with rivaroxaban 15 mg vs 1.4% with low-dose aspirin (absolute risk difference 0.6%; 95% CI -1.8 to 0.5) with numerically higher major bleeding with rivaroxaban (1.6% vs 0.6%; HR 2.5; 95% CI 0.8-8.0); the trial was stopped early for futility
D. The trial was stopped early for efficacy after demonstrating rivaroxaban reduced major bleeding compared with aspirin (HR 0.40; 95% CI 0.12-0.90)
E. Covert embolic stroke detected by MRI was excluded from the primary endpoint, which included only clinical stroke and systemic embolism, and overall stroke rates remained markedly higher than in the general population without AF

Correct Answer: C

C describes the true OCEAN design and results:

  • Population: Successful catheter ablation for AF at least 1 year earlier, success confirmed by Holter monitoring including 48-hour monitoring within 2 months of enrollment, CHA2DS2-VASc ≥1 (men) or ≥2 (women). Mean age 66 years, ~75% had only a single ablation, ~2/3 had paroxysmal AF. Balanced at baseline. Intention-to-treat analysis.
  • Intervention: Rivaroxaban 15 mg daily (not 20 mg) vs low-dose aspirin, median follow-up 3 years. MRI brain at baseline and end of follow-up to detect covert embolic strokes, which were included in the primary outcome.
  • Results - No significant difference, stopped for futility, not efficacy:
    • Primary outcome (stroke + systemic embolism + covert stroke): 5 patients rivaroxaban (0.8%) vs 9 aspirin (1.4%); absolute risk difference 0.6% (95% CI, -1.8 to 0.5) - CI crosses 0, no superiority. Trial stopped early for futility.
    • Major bleeding numerically more often with rivaroxaban: 1.6% vs 0.6%; HR 2.5 (95% CI 0.8-8.0) - CI crosses 1.0, so not statistically significant, but point estimate favors aspirin. Net clinical benefit is a wash.
    • Overall stroke rate was low and similar to people without a history of AF.

Why Other Options Are Incorrect:

  • A - Incorrect on 4 points: Wrong CHA2DS2-VASc threshold (≥1 men/≥2 women, not ≥2/≥3), wrong timing (≥1 year, not within 6 months), wrong rivaroxaban dose (15 mg in trial, not 20 mg), wrong endpoint (primary included covert stroke by MRI, not clinical stroke alone).
  • B - Incorrect statistical interpretation: Although event rates 0.8% vs 1.4% are correct, the CI (-1.8 to 0.5) includes no difference and p was not significant. Rivaroxaban did not significantly reduce the composite.
  • D - Incorrect reason for stopping and direction of bleeding: Trial stopped for futility, not efficacy, and bleeding was numerically higher with rivaroxaban (HR 2.5), not lower (HR 0.40 is the inverse).
  • E - Incorrect endpoint and background risk: Covert stroke was included in primary endpoint, and overall stroke rate was not markedly higher - it was low, similar to non-AF population, supporting safety of de-escalation.

Study Design: Randomized controlled trial (single-blinded), concealed allocation, outpatient setting. Funding: government, foundation, and industry. Level of Evidence = 1b.

Bottom Line / Clinical Application: In patients with Holter-confirmed successful ablation ≥1 year ago who meet low-moderate CHA2DS2-VASc criteria, continuing rivaroxaban 15 mg offers no significant reduction in stroke/systemic embolism/covert stroke vs low-dose aspirin over 3 years, with a signal toward more major bleeding. Risk/benefit discussion about de-escalation to aspirin is reasonable, but does not apply to patients with early ablation (<1 year), documented recurrence, or higher thromboembolic risk outside trial criteria.

500

A 62-year-old woman has resistant hypertension on maximally tolerated lisinopril, amlodipine, and chlorthalidone, with office BP 148/92 mm Hg despite adherence and correct measurement technique. Basic metabolic panel shows K+ 4.0 mEq/L, eGFR 52 mL/min/1.73m². She asks about next steps. Regarding resistant hypertension evaluation and management per the 2025 AHA/ACC guideline, which statement is most accurate?

A. Secondary causes are rare and affect <1% of hypertensive patients; screening for primary aldosteronism is only indicated if hypokalemia is present, and all antihypertensives must be stopped before screening
B. Screen for primary aldosteronism, which affects up to 22% of patients with stage 2 hypertension and can be present with normal potassium; screening is with plasma aldosterone and renin activity, only mineralocorticoid receptor antagonists need be stopped beforehand; if positive, consider adrenal imaging and add spironolactone as 4th agent if eGFR ≥45; also evaluate for obstructive sleep apnea
C. Renal artery stenosis affects >25% of hypertensive patients and revascularization improves outcomes vs medical therapy
D. Orthostatic hypotension is worsened by BP control and is a contraindication to intensification, and all BP medications must be stopped perioperatively
E. Perioperative management requires stopping beta-blockers to improve outcomes

Correct Answer: B

Explanation:
Resistant Hypertension Pearl - High yield for boards:

  • Secondary causes affect up to 25% of hypertensive patients, especially with higher BP, treatment resistance, sudden/early-onset hypertension. Primary aldosteronism affects up to 22% of patients with stage 2 hypertension. Moderate-severe obstructive sleep apnea also associated with hypertension and CVD events.
  • Screening for primary aldosteronism recommended in resistant hypertension (and also consider in hypokalemia, OSA, adrenal incidentaloma, family history early-onset hypertension/stroke <40 years). Normal potassium does NOT rule it out - >50% of primary aldosteronism patients do NOT have hypokalemia (this patient K+ 4.0 does not exclude it).
  • How to screen: Plasma aldosterone and renin activity. Typical positive: renin suppressed <1 ng/mL/hr, aldosterone ≥10 ng/dL (277 pmol/L), aldosterone:renin ratio ≥30.
  • Medication management for screening: Only mineralocorticoid receptor antagonists (spironolactone/eplerenone) should be stopped; most other agents can be continued to avoid delaying screening.
  • If positive: Consider adrenal imaging and add mineralocorticoid receptor antagonist such as spironolactone as 4th medication in uncontrolled resistant hypertension already taking ACEi/ARB + CCB + thiazide-type diuretic, assuming eGFR ≥45 mL/min/1.73m² (patient eGFR 52 qualifies). At 2-4 weeks after initiation or titration of ACEi/ARB/diuretic/MRA, check basic metabolic panel for K+, sodium, creatinine. Alternative 4th-line: amiloride, beta-blocker, alpha-blocker, central sympatholytic, direct vasodilator. Aprocitentan (dual endothelin antagonist) and renal denervation may be reasonable adjuncts (denervation benefit uncertain).
  • Obstructive sleep apnea coexists frequently with primary aldosteronism. CPAP can reduce systolic BP up to 5 mm Hg, 8 mm Hg with weight loss. Weight loss alone has limited effect on BP in OSA.
  • Renal artery stenosis is rare (<5% of hypertension) and revascularization does NOT improve outcomes vs medical therapy alone - so C is wrong.
  • Orthostatic hypotension: Affects up to 10% of hypertensive patients, especially older adults. More intensive BP treatment REDUCES risk and does NOT reduce benefits of treatment - intensification still beneficial.
  • Perioperative: Most medications can be continued through perioperative period. Continuing beta-blockers improves outcomes when included in goal-directed therapy. Stopping ACEi/ARB 24 hours before noncardiac surgery to reduce hypotension/CV events is controversial - large RCT showed no improvement.

Follow-up after medication initiation: Basic metabolic panel 2-4 weeks after starting/titrating ACEi, ARB, diuretic, or MRA.

Pregnancy pearl (additional high-yield context): For chronic hypertension in pregnancy, treat to <140/90 mm Hg to reduce maternal/perinatal morbidity. If SBP ≥160 or DBP ≥110 on repeat within 15 minutes, immediate treatment to <160/110 within 30-60 minutes. Use labetalol or extended-release nifedipine; avoid ACEi, ARB, renin inhibitors, nitroprusside, MRAs; offer aspirin 81 mg/day to reduce preeclampsia risk.

M
e
n
u